首页> 外文期刊>中国神经再生研究(英文版) >Kai Xin San ameliorates scopolamine-induced cognitive dysfunction
【24h】

Kai Xin San ameliorates scopolamine-induced cognitive dysfunction

机译:开心散改善东pol碱所致的认知功能障碍

获取原文
获取原文并翻译 | 示例
       

摘要

Kai Xin San (KXS, containing ginseng, hoelen, polygala, and acorus), a traditional Chinese herbal compound, has been found to regulate cognitive dysfunction; however, its mechanism of action is still unclear. In this study, 72 specific-pathogen-free male Kunming mice aged 8 weeks were randomly divided into a vehicle control group, scopolamine group, low-dose KXS group, moderate-dose KXS group, high-dose KXS group, and positive control group. Except for the vehicle control group and scopolamine groups (which received physiological saline), the doses of KXS (0.7, 1.4 and 2.8 g/kg per day) and donepezil (3 mg/kg per day) were gastrointestinally administered once daily for 2 weeks. On day 8 after intragastric treatment, the behavioral tests were carried out. Scopolamine group and intervention groups received scopol-amine 3 mg/kg per day through intraperitoneal injection. The effects of KXS on spatial learning and memory, pathological changes of brain tissue, expression of apoptosis factors, oxidative stress injury factors, synapse-associated protein, and cholinergic neurotransmitter were mea-sured. The results confirmed the following. (1) KXS shortened the escape latency and increased residence time in the target quadrant and the number of platform crossings in the Morris water maze. (2) KXS increased the percentage of alternations between the labyrinth arms in the mice of KXS groups in the Y-maze. (3) Nissl and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling staining revealed that KXS promoted the production of Nissl bodies and inhibited the formation of apoptotic bodies. (4) Western blot assay showed that KXS up-regulated the expression of anti-apoptotic protein Bcl-2 and inhibited the expression of pro-apoptotic protein Bax. KXS up-regulated the expression of postsynaptic density 95, synaptophysin, and brain-derived neurotrophic factor in the cerebral cortex and hippocampus. (5) KXS increased the level and activity of choline acetyltransferase, acetylcholine, superoxide dismutase, and glutathione peroxidase, and re-duced the level and activity of acetyl cholinesterase, reactive oxygen species, and malondialdehyde through acting on the cholinergic system and reducing oxidative stress damage. These results indicate that KXS plays a neuroprotective role and improves cognitive function through reducing apoptosis and oxidative stress, and regulating synapse-associated protein and cholinergic neurotransmitters.
机译:已发现传统的中草药化合物开新散(KXS,包含人参,,远志和鸡耳草)可调节认知功能障碍。但是,其作用机理仍不清楚。在这项研究中,将72只8周大的无特定病原体的雄性昆明小鼠随机分为媒介物对照组,东pol碱组,低剂量KXS组,中剂量KXS组,高剂量KXS组和阳性对照组。除溶媒对照组和东pol碱组(接受生理盐水)外,每天胃肠道两次服用KXS(每天0.7、1.4和2.8 g / kg)和多奈哌齐(每天3 mg / kg) 。胃内治疗后第8天,进行了行为测试。东co碱组和干预组每天通过腹膜内注射接受东3碱3 mg / kg。测量了KXS对空间学习和记忆,脑组织病理变化,细胞凋亡因子,氧化应激损伤因子,突触相关蛋白和胆碱能神经递质表达的影响。结果证实了以下内容。 (1)KXS缩短了逃逸潜伏期,并增加了在目标象限的停留时间以及莫里斯水迷宫中的平台穿越次数。 (2)KXS增加了Y迷宫中KXS组小鼠的迷宫臂间交替的百分比。 (3)Nissl和末端脱氧核苷酸转移酶介导的dUTP缺口末端标记染色显示,KXS促进了Nissl体的产生并抑制了凋亡小体的形成。 (4)Western blot检测结果表明,KXS上调抗凋亡蛋白Bcl-2的表达,并抑制促凋亡蛋白Bax的表达。 KXS上调了大脑皮层和海马中突触后密度95,突触素和脑源性神经营养因子的表达。 (5)KXS通过作用于胆碱能系统并减轻氧化应激而增加了胆碱乙酰转移酶,乙酰胆碱,超氧化物歧化酶和谷胱甘肽过氧化物酶的水平和活性,并降低了乙酰胆碱酯酶,活性氧和丙二醛的水平和活性。损伤。这些结果表明,KXS通过减少细胞凋亡和氧化应激,调节突触相关蛋白和胆碱能神经递质,发挥神经保护作用并改善认知功能。

著录项

  • 来源
    《中国神经再生研究(英文版)》 |2019年第5期|794-804|共11页
  • 作者单位

    Institute of Clinical Pharmacology,Guangzhou University of Chinese Medicine,Guangzhou,Guangdong Province,China;

    First Affiliated Hospital of Henan University of Chinese Medicine,Zhengzhou,Henan Province,China;

    Institute of Clinical Pharmacology,Guangzhou University of Chinese Medicine,Guangzhou,Guangdong Province,China;

    Institute of Clinical Pharmacology,Guangzhou University of Chinese Medicine,Guangzhou,Guangdong Province,China;

    First Affiliated Hospital of Guangzhou University of Chinese Medicine,Guangzhou,Guangdong Province,China;

    Institute of Clinical Pharmacology,Guangzhou University of Chinese Medicine,Guangzhou,Guangdong Province,China;

    Department of Neurology,The First Affiliated Hospital,Guangzhou Medical University,Guangzhou,China;

    Institute of Clinical Pharmacology,Guangzhou University of Chinese Medicine,Guangzhou,Guangdong Province,China;

    Guangdong Provincial Hospital of Chinese Medicine,Guangzhou,Guangdong Province,China;

    Institute of Clinical Pharmacology,Guangzhou University of Chinese Medicine,Guangzhou,Guangdong Province,China;

    Guangdong Provincial Hospital of Chinese Medicine,Guangzhou,Guangdong Province,China;

    School of Food and Pharmaceutical Engineering,Zhaoqing University,Zhaoqing,Guangdong Province,China;

    Institute of Clinical Pharmacology,Guangzhou University of Chinese Medicine,Guangzhou,Guangdong Province,China;

    Institute of Clinical Pharmacology,Guangzhou University of Chinese Medicine,Guangzhou,Guangdong Province,China;

    Institute of Clinical Pharmacology,Guangzhou University of Chinese Medicine,Guangzhou,Guangdong Province,China;

    Institute of Clinical Pharmacology,Guangzhou University of Chinese Medicine,Guangzhou,Guangdong Province,China;

    Institute of Clinical Pharmacology,Guangzhou University of Chinese Medicine,Guangzhou,Guangdong Province,China;

    Institute of Clinical Pharmacology,Guangzhou University of Chinese Medicine,Guangzhou,Guangdong Province,China;

    Institute of Clinical Pharmacology,Guangzhou University of Chinese Medicine,Guangzhou,Guangdong Province,China;

  • 收录信息 中国科学引文数据库(CSCD);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药物疗法、化学疗法;病理生理学;神经病学;
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号